Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Predictors for Improvement in Patient-Reported Outcomes in Complement Inhibitor–Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab and Ravulizumab
  2. Association of Glycaemic Index and Glycaemic Load With Risk of Type 2 Diabetes
  3. Association of Intake of SGLT2 Inhibitors With Functional Capacity and Quality of Life in Patients With Heart Failure
  4. Dosing Patterns of Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab in the US
  5. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
  6. Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria: Use, Clinical Effectiveness, and Influence on HRQoL and Productivity
  7. Effects of Statin Therapy on Diagnoses of New-Onset Diabetes and Worsening Glycaemia
  8. SGLT2 Inhibitors Influence Skeletal Muscle Pathology in Patients With HFrEF
  9. Association of ADHD Pharmacotherapy With Mortality in Individuals With ADHD
  10. Exposure–Response Associations Between Chronic Exposure to Fine Particulate Matter and Risks of Hospital Admission for Major CVD

Most Read This Week

Recently Updated